Efecto del uso de metformina y combinaciones orales en diabetes mellitus tipo II sobre el riesgo y pronóstico de la enfermedad cardiovascular: revisión sistemática
ilustraciones, graficas, diagramas
- Autores:
-
Sierra Sánchez, Karen Tatiana
- Tipo de recurso:
- Fecha de publicación:
- 2021
- Institución:
- Universidad Nacional de Colombia
- Repositorio:
- Universidad Nacional de Colombia
- Idioma:
- spa
- OAI Identifier:
- oai:repositorio.unal.edu.co:unal/81150
- Palabra clave:
- 610 - Medicina y salud
Metformina
Metformin
Diabetes Mellitus
Review
Diabetes Mellitus
Revisión
Diabetes mellitus tipo 2
Riesgo cardiovascular
Antidiabeticos orales
Type 2 Diabetes Mellitus
Cardiovascular risk
Oral antidiabetics
- Rights
- openAccess
- License
- Reconocimiento 4.0 Internacional
| id |
UNACIONAL2_4c8086b651c5403616f30153c10d87e9 |
|---|---|
| oai_identifier_str |
oai:repositorio.unal.edu.co:unal/81150 |
| network_acronym_str |
UNACIONAL2 |
| network_name_str |
Universidad Nacional de Colombia |
| repository_id_str |
|
| dc.title.spa.fl_str_mv |
Efecto del uso de metformina y combinaciones orales en diabetes mellitus tipo II sobre el riesgo y pronóstico de la enfermedad cardiovascular: revisión sistemática |
| dc.title.translated.eng.fl_str_mv |
Effect of the use of metformin and combinations in type II diabetes mellitus on the risk and prognosis of cardiovascular diseases: systematic review |
| title |
Efecto del uso de metformina y combinaciones orales en diabetes mellitus tipo II sobre el riesgo y pronóstico de la enfermedad cardiovascular: revisión sistemática |
| spellingShingle |
Efecto del uso de metformina y combinaciones orales en diabetes mellitus tipo II sobre el riesgo y pronóstico de la enfermedad cardiovascular: revisión sistemática 610 - Medicina y salud Metformina Metformin Diabetes Mellitus Review Diabetes Mellitus Revisión Diabetes mellitus tipo 2 Riesgo cardiovascular Antidiabeticos orales Type 2 Diabetes Mellitus Cardiovascular risk Oral antidiabetics |
| title_short |
Efecto del uso de metformina y combinaciones orales en diabetes mellitus tipo II sobre el riesgo y pronóstico de la enfermedad cardiovascular: revisión sistemática |
| title_full |
Efecto del uso de metformina y combinaciones orales en diabetes mellitus tipo II sobre el riesgo y pronóstico de la enfermedad cardiovascular: revisión sistemática |
| title_fullStr |
Efecto del uso de metformina y combinaciones orales en diabetes mellitus tipo II sobre el riesgo y pronóstico de la enfermedad cardiovascular: revisión sistemática |
| title_full_unstemmed |
Efecto del uso de metformina y combinaciones orales en diabetes mellitus tipo II sobre el riesgo y pronóstico de la enfermedad cardiovascular: revisión sistemática |
| title_sort |
Efecto del uso de metformina y combinaciones orales en diabetes mellitus tipo II sobre el riesgo y pronóstico de la enfermedad cardiovascular: revisión sistemática |
| dc.creator.fl_str_mv |
Sierra Sánchez, Karen Tatiana |
| dc.contributor.advisor.none.fl_str_mv |
Becerra-Camargo, Jesus Crosby, Milton Josué |
| dc.contributor.author.none.fl_str_mv |
Sierra Sánchez, Karen Tatiana |
| dc.contributor.researchgroup.spa.fl_str_mv |
Fortalecimiento Institucional de Servicios Farmacéuticos |
| dc.subject.ddc.spa.fl_str_mv |
610 - Medicina y salud |
| topic |
610 - Medicina y salud Metformina Metformin Diabetes Mellitus Review Diabetes Mellitus Revisión Diabetes mellitus tipo 2 Riesgo cardiovascular Antidiabeticos orales Type 2 Diabetes Mellitus Cardiovascular risk Oral antidiabetics |
| dc.subject.decs.eng.fl_str_mv |
Metformina Metformin Diabetes Mellitus Review |
| dc.subject.decs.spa.fl_str_mv |
Diabetes Mellitus Revisión |
| dc.subject.proposal.spa.fl_str_mv |
Diabetes mellitus tipo 2 Riesgo cardiovascular Antidiabeticos orales |
| dc.subject.proposal.eng.fl_str_mv |
Type 2 Diabetes Mellitus Cardiovascular risk Oral antidiabetics |
| description |
ilustraciones, graficas, diagramas |
| publishDate |
2021 |
| dc.date.issued.none.fl_str_mv |
2021-12-14 |
| dc.date.accessioned.none.fl_str_mv |
2022-03-08T15:27:36Z |
| dc.date.available.none.fl_str_mv |
2022-03-08T15:27:36Z |
| dc.type.spa.fl_str_mv |
Trabajo de grado - Maestría |
| dc.type.driver.spa.fl_str_mv |
info:eu-repo/semantics/masterThesis |
| dc.type.version.spa.fl_str_mv |
info:eu-repo/semantics/acceptedVersion |
| dc.type.content.spa.fl_str_mv |
Text |
| dc.type.redcol.spa.fl_str_mv |
http://purl.org/redcol/resource_type/TM |
| status_str |
acceptedVersion |
| dc.identifier.uri.none.fl_str_mv |
https://repositorio.unal.edu.co/handle/unal/81150 |
| dc.identifier.instname.spa.fl_str_mv |
Universidad Nacional de Colombia |
| dc.identifier.reponame.spa.fl_str_mv |
Repositorio Institucional Universidad Nacional de Colombia |
| dc.identifier.repourl.spa.fl_str_mv |
https://repositorio.unal.edu.co/ |
| url |
https://repositorio.unal.edu.co/handle/unal/81150 https://repositorio.unal.edu.co/ |
| identifier_str_mv |
Universidad Nacional de Colombia Repositorio Institucional Universidad Nacional de Colombia |
| dc.language.iso.spa.fl_str_mv |
spa |
| language |
spa |
| dc.relation.references.spa.fl_str_mv |
1. Resources and tools [Internet]. [cited 2021 Oct 26]. Available from: https://www.idf.org/our-activities/advocacy-awareness/resources-and-tools/129-globaldiabetes- plan-2011-2021.html 2. Situación de la enfermedad renal crónica, la hipertensión arterial y diabetes mellitus en Colombia 2020 | Cuenta de Alto Costo [Internet]. [cited 2021 Oct 27]. Available from: https://cuentadealtocosto.org/site/publicaciones/situacion-de-la-enfermedad-renalcronica- la-hipertension-arterial-y-diabetes-mellitus-en-colombia-2020/ 3. Dalama B, Mesa J. Nuevos hipoglucemiantes orales y riesgo cardiovascular. Cruzando la frontera metabólica. Revista Española de Cardiología [Internet]. 2016 Nov 1 [cited 2021 Oct 27];69(11):1088–97. Available from: http://www.revespcardiol.org/es-nuevoshipoglucemiantes- orales-riesgo-cardiovascular--articulo-S0300893216303785 4. SM H, S L, T R, K P, M L. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. The New England journal of medicine [Internet]. 1998 Jul 23 [cited 2021 Oct 27];339(4):229–34. Available from: https://pubmed.ncbi.nlm.nih.gov/9673301/ 5. María Del Pilar D, Sansone S. Antidiabéticos orales y riesgo cardiovascular María del Pilar Serra Sansone Antidiabéticos orales y riesgo cardiovascular Epidemiología de la diabetes y riesgo de enfermedad cardiovascular. 6. La historia de la rosiglitazona: mensajes clave [Internet]. [cited 2021 Oct 27]. Available from: https://www.elsevier.es/es-revista-endocrinologia-nutricion-12-pdf- S1575092210002469 7. TM L, TF C. Impairment of myocardial protection in type 2 diabetic patients. The Journal of clinical endocrinology and metabolism [Internet]. 2003 Feb 1 [cited 2021 Oct 27];88(2):531–7. Available from: https://pubmed.ncbi.nlm.nih.gov/12574175/ 8. Páginas - Enfermedades cardiovasculares [Internet]. [cited 2021 Oct 27]. Available from: https://www.minsalud.gov.co/salud/publica/PENT/Paginas/enfermedadescardiovasculares. aspx 9. A P, D M-W, UA M, R L, M N, G F, et al. Definition, Classification and Diagnosis of Diabetes Mellitus. Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association [Internet]. 2019 [cited 2021 Oct 27];127(S 01):S1–7. Available from: https://pubmed.ncbi.nlm.nih.gov/31860923/ 10. Atlas De La Diabetes De La Fid 9a Edici n 2019 [Internet]. [cited 2021 Oct 27]. Available from: https://diabetesatlas.org/es/ 11. Epidemiología de la diabetes en Colombia [Internet]. [cited 2021 Oct 27]. Available from: https://www.elsevier.es/es-revista-avances-diabetologia-326-pdf-S1134323010620054 12. Mata-Cases M, FernáNdez-Bertolín E, García-Dur M, Cos-Claramunt X, Pareja-Rossell C, Pujol-Ribera E. doi:10.1016/j.gaceta.2008.05.007. GACETA Sanitaria. 23:133–8. 13. Ruiz-García A, Arranz-Martínez E, García- Álvarez JC, García-Fernández ME, Palacios- Mart nez D, Montero-Costa A, et al. Prevalencia de diabetes mellitus en el ámbito de la atención primaria española y su asociación con factores de riesgo cardiovascular y enfermedades cardiovasculares. Estudio SIMETAP-DM. Clínica e Investigación en Arteriosclerosis. 2020 Jan 1;32(1):15–26. 14. stenson CG. The pathophysiology of type 2 diabetes mellitus: An overview. Acta Physiologica Scandinavica. 2001;171(3):241–7. 15. RJ H. Type-2 diabetes mellitus and cardiovascular disease. Future cardiology [Internet]. 2018 Nov 1 [cited 2021 Oct 27];14(6):491–509. Available from: https://pubmed.ncbi.nlm.nih.gov/30409037/ 16. Petrie JR, Guzik TJ, Touyz RM. Diabetes, Hypertension, and Cardiovascular Disease: Clinical Insights and Vascular Mechanisms. The Canadian Journal of Cardiology [Internet]. 2018 May 1 [cited 2021 Oct 27];34(5):575. Available from: /pmc/articles/PMC5953551/ 17. Complicaciones de la diabetes mellitus. Diagn stico y tratamiento [Internet]. [cited 2021 Oct 27]. Available from: https://www.elsevier.es/es-revista-medicina-familia-semergen-40- pdf-S1138359301739317 18. Dr. Roberto González Dr. Edgar Mora Brito. ALAD. 2019 [cited 2021 Oct 27]; Available from: www.revistaalad.com 19. ADA-Standards-of-Medical-Care-Diabetes-Care-2021. ADA-Standards-of-Medical-Care- Diabetes-Care-2021 [Internet]. [cited 2021 Dec 12]. Available from: https://www.fipec.net/wp-content/uploads/2021/04/ADA-Standards-of-Medical-Care- Diabetes-Care-2021.pdf 20. Vista de Metformina: m s all del control glucémico [Internet]. [cited 2021 Oct 27]. Available from: https://revistas.uis.edu.co/index.php/revistamedicasuis/article/view/6308/6532 21. Alfonso Figueredo E, Andrés Reyes Sanamé F, Luisa Pérez Álvarez M, Batista Acosta Y, Pe a Garcell Hospital General Docente Y, Luis Fernández Hernández Baquero G. Inhibidores de la dipeptidil peptidasa 4 y una nueva estrategia farmacológica en la diabetes mellitus tipo 2 Inhibitors of dipeptidil peptidase 4 new pharmacologic strategic in the diabetes mellitus type 2. Revista Cubana de Medicina [Internet]. 2016 [cited 2021 Oct 27];55(3). Available from: http://scielo.sld.cu 22. Revista Cubana de Endocrinología. 2020(Sep-Dic);31(3):e250. [cited 2021 Oct 27]; Available from: https://orcid.org/0000-0001-5163--8045 23. Versión 5.1.0. [cited 2021 Oct 27]; Available from: www.cochrane-handbook.org. 24. Fau C, Nabzo S. Metaan lisis: bases conceptuales, análisis e interpretación estadística Meta-analysis: Conceptual bases, statistical analysis and interpretation. Rev Mex Oftalmol [Internet]. 2020 [cited 2021 Dec 12];94(6):260–73. Available from: www.rmo.com.mx 25. Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. European Heart Journal. 2020 Jan 1;41(2):255–323. 26. Bethel MA, Green JB, Milton J, Tajar A, Engel SS, Califf RM, et al. Regional, age and sex differences in baseline characteristics of patients enrolled in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS). Diabetes, Obesity and Metabolism. 2015 Apr 1;17(4):395–402. 27. Terenzi DC, Verma S, Trac JZ, Quan A, Mason T, Al-Omran M, et al. P317A novel role of SGLT2 inhibitors to increase circulating proangiogenic progenitor cells in patients with type 2 diabetes and cardiovascular disease: A sub-study of the EMPA-HEART CardioLink-6 Trial. European Heart Journal [Internet]. 2019 Oct 1 [cited 2021 Oct 30];40(Supplement_1). Available from: https://academic.oup.com/eurheartj/article/40/Supplement_1/ehz747.0152/5594325 28. Conference Abstract - A diabetes risk score for cardiovascular events in primary and secondary prevention: Observations from the SAVOR-TIMI 53 study [Internet]. [cited 2021 Oct 30]. Available from: https://www.mdlinx.com/surgery/conferenceabstract. cfm/52401/?nonus=0&searchstring=&coverage_day=0&page=2 29. N I, H O, H S, N F, S K, K K. SYR-472, a novel once-weekly dipeptidyl peptidase-4 (DPP-4) inhibitor, in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebocontrolled trial. The lancet Diabetes & endocrinology [Internet]. 2014 Feb [cited 2021 Oct 30];2(2):125–32. Available from: https://pubmed.ncbi.nlm.nih.gov/24622716/ 30. CE C, KC U, TH C, TH L, YJ W, KL W, et al. 2020 Consensus of Taiwan Society of Cardiology on the pharmacological management of patients with type 2 diabetes and cardiovascular diseases. Journal of the Chinese Medical Association : JCMA [Internet]. 2020 Jul 1 [cited 2021 Oct 30];83(7):587–621. Available from: https://pubmed.ncbi.nlm.nih.gov/32628427/ 31. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. http://dx.doi.org/101056/NEJMoa1504720 [Internet]. 2015 Nov 25 [cited 2021 Oct 27];13(1):17–8. Available from: https://www.nejm.org/doi/full/10.1056/nejmoa1504720 32. McMurray JJV, Solomon SD, Inzucchi SE, K ber L, Kosiborod MN, Martinez FA, et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. https://doi.org/101056/NEJMoa1911303 [Internet]. 2019 Sep 19 [cited 2021 Oct 92 27];381(21):1995–2008. Available from: https://www.nejm.org/doi/full/10.1056/NEJMoa1911303 33. Rosenstock J, Perkovic V, Johansen OE, Cooper ME, Kahn SE, Marx N, et al. Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial. JAMA [Internet]. 2019 Jan 1 [cited 2021 Oct 27];321(1):69–79. Available from: https://jamanetwork.com/journals/jama/fullarticle/2714646 34. Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, et al. Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus. http://dx.doi.org/101056/NEJMoa1307684 [Internet]. 2013 Oct 2 [cited 2021 Oct 27];369(14):1317–26. Available from: https://www.nejm.org/doi/full/10.1056/nejmoa1307684 35. Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, et al. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. http://dx.doi.org/101056/NEJMoa1501352 [Internet]. 2015 Jul 15 [cited 2021 Oct 27];373(3):232–42. Available from: https://www.nejm.org/doi/full/10.1056/nejmoa1501352 36. Turner R. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). The Lancet [Internet]. 1998 Sep 12 [cited 2021 Oct 27];352(9131):854–65. Available from: http://www.thelancet.com/article/S0140673698070378/fulltext 37. Lee K-T, Yeh Y-H, Chang S-H, See L-C, Lee C-H, Wu L-S, et al. Metformin is associated with fewer major adverse cardiac events among patients with a new diagnosis of type 2 diabetes mellitus: A propensity score-matched nationwide study. Medicine [Internet]. 2017 Jul 1 [cited 2021 Oct 27];96(28). Available from: /pmc/articles/PMC5515773/ 38. Asociación entre la edad del diagnóstico de diabetes tipo 2 y la gravedad del trastorno. Revista Panamericana de Salud Pública. 2003 Dec;14(6):434–5. 39. Wilcox T, de Block C, Schwartzbard AZ, Newman JD. Diabetic Agents, From Metformin to SGLT2 Inhibitors and GLP1 Receptor Agonists: JACC Focus Seminar. Journal of the American College of Cardiology. 2020 Apr 28;75(16):1956–74. 40. Palmer SC, Tendal B, Mustafa RA, Vandvik PO, Li S, Hao Q, et al. Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials. The BMJ [Internet]. 2021 Jan 13 [cited 2021 Oct 30];372. Available from: /pmc/articles/PMC7804890/ 41. Nunes JPL, Rodrigues JD, Mel o F. Acute myocardial infarction associated to DPP-4 inhibitors. Heart, Lung and Vessels [Internet]. 2014 [cited 2021 Oct 30];6(3):180. Available from: /pmc/articles/PMC4181279/ 42. Zheng SL, Roddick AJ, Aghar-Jaffar R, Shun-Shin MJ, Francis D, Oliver N, et al. Association Between Use of Sodium-Glucose Cotransporter 2 Inhibitors, Glucagon-like Peptide 1 93 Agonists, and Dipeptidyl Peptidase 4 Inhibitors With All-Cause Mortality in Patients With Type 2 Diabetes: A Systematic Review and Meta-analysis. JAMA [Internet]. 2018 Apr 17 [cited 2021 Oct 30];319(15):1580. Available from: /pmc/articles/PMC5933330/ 43. Scheen AJ. Cardiovascular Effects of New Oral Glucose-Lowering Agents: DPP-4 and SGLT-2 Inhibitors. Circulation Research [Internet]. 2018 May 1 [cited 2021 Oct 30];122(10):1439. Available from: /pmc/articles/PMC5959222/ 44. Galvus | European Medicines Agency [Internet]. [cited 2021 Dec 12]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/galvus 45. Davies MJ, D’Alessio DA, Fradkin J, Kernan WN, Mathieu C, Mingrone G, et al. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2018 61:12 [Internet]. 2018 Oct 5 [cited 2022 Jan 28];61(12):2461–98. Available from: https://link.springer.com/article/10.1007/s00125-018-4729-5 46. Foretz M, Guigas B, Bertrand L, Pollak M, Viollet B. Metformin: From Mechanisms of Action to Therapies. Cell Metabolism [Internet]. 2014 Dec 2 [cited 2022 Jan 29];20(6):953–66. Available from: http://www.cell.com/article/S1550413114004410/fulltext 47. Madiraju AK, Erion DM, Rahimi Y, Zhang XM, Braddock DT, Albright RA, et al. Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase. Nature [Internet]. 2014 [cited 2022 Jan 29];510(7506):542. Available from: /pmc/articles/PMC4074244/ 48. Foretz M, Guigas B, Viollet B. Understanding the glucoregulatory mechanisms of metformin in type 2 diabetes mellitus. Nature Reviews Endocrinology [Internet]. 2019 Aug 22 [cited 2022 Jan 29];15(10):569–89. Available from: https://www.hal.inserm.fr/inserm-02277186 49. Bromage DI, Godec TR, Pujades-Rodriguez M, Gonzalez-Izquierdo A, Denaxas S, Hemingway H, et al. Metformin use and cardiovascular outcomes after acute myocardial infarction in patients with type 2 diabetes: a cohort study. Cardiovascular Diabetology [Internet]. 2019 Dec 9 [cited 2021 Oct 30];18(1). Available from: /pmc/articles/PMC6900858/ 50. Conceptos fundamentales de las revisiones sistemáticas/metaanálisis [Internet]. [cited 2021 Dec 12]. Available from: https://www.elsevier.es/es-revista-urologia-colombiana-398- pdf-S0120789X15000076 51. Gamble J-M, Thomas JM, Twells LK, Midodzi WK, Majumdar SR. Comparative effectiveness of incretin-based therapies and the risk of death and cardiovascular events in 38,233 metformin monotherapy users. Medicine [Internet]. 2016 Jun 1 [cited 2021 Oct 30];95(26). Available from: /pmc/articles/PMC4937919/ |
| dc.rights.coar.fl_str_mv |
http://purl.org/coar/access_right/c_abf2 |
| dc.rights.license.spa.fl_str_mv |
Reconocimiento 4.0 Internacional |
| dc.rights.uri.spa.fl_str_mv |
http://creativecommons.org/licenses/by/4.0/ |
| dc.rights.accessrights.spa.fl_str_mv |
info:eu-repo/semantics/openAccess |
| rights_invalid_str_mv |
Reconocimiento 4.0 Internacional http://creativecommons.org/licenses/by/4.0/ http://purl.org/coar/access_right/c_abf2 |
| eu_rights_str_mv |
openAccess |
| dc.format.extent.spa.fl_str_mv |
93 páginas |
| dc.format.mimetype.spa.fl_str_mv |
application/pdf |
| dc.publisher.spa.fl_str_mv |
Universidad Nacional de Colombia |
| dc.publisher.program.spa.fl_str_mv |
Bogotá - Ciencias - Maestría en Ciencias - Farmacología |
| dc.publisher.department.spa.fl_str_mv |
Departamento de Farmacia |
| dc.publisher.faculty.spa.fl_str_mv |
Facultad de Ciencias |
| dc.publisher.place.spa.fl_str_mv |
Bogotá, Colombia |
| dc.publisher.branch.spa.fl_str_mv |
Universidad Nacional de Colombia - Sede Bogotá |
| institution |
Universidad Nacional de Colombia |
| bitstream.url.fl_str_mv |
https://repositorio.unal.edu.co/bitstream/unal/81150/5/53161452.2021.pdf https://repositorio.unal.edu.co/bitstream/unal/81150/6/license.txt https://repositorio.unal.edu.co/bitstream/unal/81150/7/53161452.2021.pdf.jpg |
| bitstream.checksum.fl_str_mv |
14b9f26c2fa16be39eb724acc0d3ca7c 8153f7789df02f0a4c9e079953658ab2 a1a93cb8acaa2710532fba776e2aefbf |
| bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 MD5 |
| repository.name.fl_str_mv |
Repositorio Institucional Universidad Nacional de Colombia |
| repository.mail.fl_str_mv |
repositorio_nal@unal.edu.co |
| _version_ |
1814089935041331200 |
| spelling |
Reconocimiento 4.0 Internacionalhttp://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccesshttp://purl.org/coar/access_right/c_abf2Becerra-Camargo, Jesus39c63f96b0c5447afcecc2eaa397be89600Crosby, Milton Josué053f3781291c7c8fae04830f285009e0Sierra Sánchez, Karen Tatianaa19eb85ccb28e2cfc657c64a5b837c8dFortalecimiento Institucional de Servicios Farmacéuticos2022-03-08T15:27:36Z2022-03-08T15:27:36Z2021-12-14https://repositorio.unal.edu.co/handle/unal/81150Universidad Nacional de ColombiaRepositorio Institucional Universidad Nacional de Colombiahttps://repositorio.unal.edu.co/ilustraciones, graficas, diagramasIntroducción: La enfermedad cardiovascular causa una de cada tres muertes en pacientes con diabetes mellitus tipo 2. La evidencia actual sobre los efectos de los fármacos antidiabeticos para controlar y reducir las complicaciones cardiovasculares es moderada y no concluyente. Objetivo: Determinar la efectividad y seguridad de la metformina y combinaciones con I-DPP4 y I-SGLT2, administrados por vía oral, como factor protector frente a enfermedades cardiovasculares. Metodología: Se realizo una revisión en las bases de datos Medline, PubMed, y Cochrane Library utilizando términos específicos. La búsqueda se realizo en ingles y español para el periodo de 2010 a 2020. La calidad de los estudios y el riesgo de sesgo fueron evaluados. Resultados: Se encontraron 911 publicaciones. Después de aplicar los criterios de inclusión y exclusión, fueron seleccionaron 13 documentos: 5 RTC, 2 estudios observacionales y otras 6 categorías (tres informes, dos RTC y una guía de diabetes). Se seleccionaron siete artículos para esta revisión. Conclusión: Esta revisión proporciona una visión general de la evidencia disponible hasta el momento sobre la eficacia y la seguridad del uso de metformina sola o en combinación de SGTL2 y I-DPP4 sobre el riego cardiovascular. Es necesario incluir nuevos estudios para actualizar el conocimiento de estas nuevas clases terapéutica utilizadas en el tratamiento de la diabetes mellitus tipo 2. Palabras clave: Diabetes mellitus tipo 2, Riesgo cardiovascular, antidiabeticos orales. (Texto tomado de la fuente)Effect of the use of metformin and oral combinations in type II diabetes mellitus on the risk and prognosis of cardiovascular disease: Systematic review. Background: Cardiovascular disease causes one in three deaths in patients with type 2 diabetes mellitus. The current evidence on the effects of antidiabetic drugs to control and reduce cardiovascular complications is low and inconclusive. Aim: To determine the effectiveness and safety of metformin and combinations with I-DPP4 and I-SGLT2, administered orally, as a protective factor against cardiovascular diseases. Method: A review was made in the PubMed, PubMed and Cochrane Library databases using specific terms. The search was made in English and Spanish, looking for publications from 2010 to 2020. Study quality and risk of bias were also assessed. Results: 911 publications were found. After applying the inclusion and exclusion criteria, 13 documents were selected: 5 RTCs, 2 observational studies, and 6 other categories (three reports, two RTCs, and one diabetes guideline). Seven articles were selected for this review. Conclusion: This review provides an overview of the evidence available to date on the efficacy and safety of the use of metformin alone or in combination of I-SGLT2 and I-DPP4 on cardiovascular risk. It is necessary to include new studies to update the knowledge of these new therapeutic classes used in the treatment of type 2 diabetes mellitus. Keywords: Type 2 Diabetes Mellitus, cardiovascular risk, oral antidiabetics.MaestríaMagíster en Ciencias - FarmacologíaUso racional de medicamentos93 páginasapplication/pdfspaUniversidad Nacional de ColombiaBogotá - Ciencias - Maestría en Ciencias - FarmacologíaDepartamento de FarmaciaFacultad de CienciasBogotá, ColombiaUniversidad Nacional de Colombia - Sede Bogotá610 - Medicina y saludMetforminaMetforminDiabetes MellitusReviewDiabetes MellitusRevisiónDiabetes mellitus tipo 2Riesgo cardiovascularAntidiabeticos oralesType 2 Diabetes MellitusCardiovascular riskOral antidiabeticsEfecto del uso de metformina y combinaciones orales en diabetes mellitus tipo II sobre el riesgo y pronóstico de la enfermedad cardiovascular: revisión sistemáticaEffect of the use of metformin and combinations in type II diabetes mellitus on the risk and prognosis of cardiovascular diseases: systematic reviewTrabajo de grado - Maestríainfo:eu-repo/semantics/masterThesisinfo:eu-repo/semantics/acceptedVersionTexthttp://purl.org/redcol/resource_type/TM1. Resources and tools [Internet]. [cited 2021 Oct 26]. Available from: https://www.idf.org/our-activities/advocacy-awareness/resources-and-tools/129-globaldiabetes- plan-2011-2021.html2. Situación de la enfermedad renal crónica, la hipertensión arterial y diabetes mellitus en Colombia 2020 | Cuenta de Alto Costo [Internet]. [cited 2021 Oct 27]. Available from: https://cuentadealtocosto.org/site/publicaciones/situacion-de-la-enfermedad-renalcronica- la-hipertension-arterial-y-diabetes-mellitus-en-colombia-2020/3. Dalama B, Mesa J. Nuevos hipoglucemiantes orales y riesgo cardiovascular. Cruzando la frontera metabólica. Revista Española de Cardiología [Internet]. 2016 Nov 1 [cited 2021 Oct 27];69(11):1088–97. Available from: http://www.revespcardiol.org/es-nuevoshipoglucemiantes- orales-riesgo-cardiovascular--articulo-S03008932163037854. SM H, S L, T R, K P, M L. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. The New England journal of medicine [Internet]. 1998 Jul 23 [cited 2021 Oct 27];339(4):229–34. Available from: https://pubmed.ncbi.nlm.nih.gov/9673301/5. María Del Pilar D, Sansone S. Antidiabéticos orales y riesgo cardiovascular María del Pilar Serra Sansone Antidiabéticos orales y riesgo cardiovascular Epidemiología de la diabetes y riesgo de enfermedad cardiovascular.6. La historia de la rosiglitazona: mensajes clave [Internet]. [cited 2021 Oct 27]. Available from: https://www.elsevier.es/es-revista-endocrinologia-nutricion-12-pdf- S15750922100024697. TM L, TF C. Impairment of myocardial protection in type 2 diabetic patients. The Journal of clinical endocrinology and metabolism [Internet]. 2003 Feb 1 [cited 2021 Oct 27];88(2):531–7. Available from: https://pubmed.ncbi.nlm.nih.gov/12574175/8. Páginas - Enfermedades cardiovasculares [Internet]. [cited 2021 Oct 27]. Available from: https://www.minsalud.gov.co/salud/publica/PENT/Paginas/enfermedadescardiovasculares. aspx9. A P, D M-W, UA M, R L, M N, G F, et al. Definition, Classification and Diagnosis of Diabetes Mellitus. Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association [Internet]. 2019 [cited 2021 Oct 27];127(S 01):S1–7. Available from: https://pubmed.ncbi.nlm.nih.gov/31860923/10. Atlas De La Diabetes De La Fid 9a Edici n 2019 [Internet]. [cited 2021 Oct 27]. Available from: https://diabetesatlas.org/es/11. Epidemiología de la diabetes en Colombia [Internet]. [cited 2021 Oct 27]. Available from: https://www.elsevier.es/es-revista-avances-diabetologia-326-pdf-S113432301062005412. Mata-Cases M, FernáNdez-Bertolín E, García-Dur M, Cos-Claramunt X, Pareja-Rossell C, Pujol-Ribera E. doi:10.1016/j.gaceta.2008.05.007. GACETA Sanitaria. 23:133–8.13. Ruiz-García A, Arranz-Martínez E, García- Álvarez JC, García-Fernández ME, Palacios- Mart nez D, Montero-Costa A, et al. Prevalencia de diabetes mellitus en el ámbito de la atención primaria española y su asociación con factores de riesgo cardiovascular y enfermedades cardiovasculares. Estudio SIMETAP-DM. Clínica e Investigación en Arteriosclerosis. 2020 Jan 1;32(1):15–26.14. stenson CG. The pathophysiology of type 2 diabetes mellitus: An overview. Acta Physiologica Scandinavica. 2001;171(3):241–7.15. RJ H. Type-2 diabetes mellitus and cardiovascular disease. Future cardiology [Internet]. 2018 Nov 1 [cited 2021 Oct 27];14(6):491–509. Available from: https://pubmed.ncbi.nlm.nih.gov/30409037/16. Petrie JR, Guzik TJ, Touyz RM. Diabetes, Hypertension, and Cardiovascular Disease: Clinical Insights and Vascular Mechanisms. The Canadian Journal of Cardiology [Internet]. 2018 May 1 [cited 2021 Oct 27];34(5):575. Available from: /pmc/articles/PMC5953551/17. Complicaciones de la diabetes mellitus. Diagn stico y tratamiento [Internet]. [cited 2021 Oct 27]. Available from: https://www.elsevier.es/es-revista-medicina-familia-semergen-40- pdf-S113835930173931718. Dr. Roberto González Dr. Edgar Mora Brito. ALAD. 2019 [cited 2021 Oct 27]; Available from: www.revistaalad.com19. ADA-Standards-of-Medical-Care-Diabetes-Care-2021. ADA-Standards-of-Medical-Care- Diabetes-Care-2021 [Internet]. [cited 2021 Dec 12]. Available from: https://www.fipec.net/wp-content/uploads/2021/04/ADA-Standards-of-Medical-Care- Diabetes-Care-2021.pdf20. Vista de Metformina: m s all del control glucémico [Internet]. [cited 2021 Oct 27]. Available from: https://revistas.uis.edu.co/index.php/revistamedicasuis/article/view/6308/653221. Alfonso Figueredo E, Andrés Reyes Sanamé F, Luisa Pérez Álvarez M, Batista Acosta Y, Pe a Garcell Hospital General Docente Y, Luis Fernández Hernández Baquero G. Inhibidores de la dipeptidil peptidasa 4 y una nueva estrategia farmacológica en la diabetes mellitus tipo 2 Inhibitors of dipeptidil peptidase 4 new pharmacologic strategic in the diabetes mellitus type 2. Revista Cubana de Medicina [Internet]. 2016 [cited 2021 Oct 27];55(3). Available from: http://scielo.sld.cu22. Revista Cubana de Endocrinología. 2020(Sep-Dic);31(3):e250. [cited 2021 Oct 27]; Available from: https://orcid.org/0000-0001-5163--804523. Versión 5.1.0. [cited 2021 Oct 27]; Available from: www.cochrane-handbook.org.24. Fau C, Nabzo S. Metaan lisis: bases conceptuales, análisis e interpretación estadística Meta-analysis: Conceptual bases, statistical analysis and interpretation. Rev Mex Oftalmol [Internet]. 2020 [cited 2021 Dec 12];94(6):260–73. Available from: www.rmo.com.mx25. Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. European Heart Journal. 2020 Jan 1;41(2):255–323.26. Bethel MA, Green JB, Milton J, Tajar A, Engel SS, Califf RM, et al. Regional, age and sex differences in baseline characteristics of patients enrolled in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS). Diabetes, Obesity and Metabolism. 2015 Apr 1;17(4):395–402.27. Terenzi DC, Verma S, Trac JZ, Quan A, Mason T, Al-Omran M, et al. P317A novel role of SGLT2 inhibitors to increase circulating proangiogenic progenitor cells in patients with type 2 diabetes and cardiovascular disease: A sub-study of the EMPA-HEART CardioLink-6 Trial. European Heart Journal [Internet]. 2019 Oct 1 [cited 2021 Oct 30];40(Supplement_1). Available from: https://academic.oup.com/eurheartj/article/40/Supplement_1/ehz747.0152/559432528. Conference Abstract - A diabetes risk score for cardiovascular events in primary and secondary prevention: Observations from the SAVOR-TIMI 53 study [Internet]. [cited 2021 Oct 30]. Available from: https://www.mdlinx.com/surgery/conferenceabstract. cfm/52401/?nonus=0&searchstring=&coverage_day=0&page=229. N I, H O, H S, N F, S K, K K. SYR-472, a novel once-weekly dipeptidyl peptidase-4 (DPP-4) inhibitor, in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebocontrolled trial. The lancet Diabetes & endocrinology [Internet]. 2014 Feb [cited 2021 Oct 30];2(2):125–32. Available from: https://pubmed.ncbi.nlm.nih.gov/24622716/30. CE C, KC U, TH C, TH L, YJ W, KL W, et al. 2020 Consensus of Taiwan Society of Cardiology on the pharmacological management of patients with type 2 diabetes and cardiovascular diseases. Journal of the Chinese Medical Association : JCMA [Internet]. 2020 Jul 1 [cited 2021 Oct 30];83(7):587–621. Available from: https://pubmed.ncbi.nlm.nih.gov/32628427/31. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. http://dx.doi.org/101056/NEJMoa1504720 [Internet]. 2015 Nov 25 [cited 2021 Oct 27];13(1):17–8. Available from: https://www.nejm.org/doi/full/10.1056/nejmoa150472032. McMurray JJV, Solomon SD, Inzucchi SE, K ber L, Kosiborod MN, Martinez FA, et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. https://doi.org/101056/NEJMoa1911303 [Internet]. 2019 Sep 19 [cited 2021 Oct 92 27];381(21):1995–2008. Available from: https://www.nejm.org/doi/full/10.1056/NEJMoa191130333. Rosenstock J, Perkovic V, Johansen OE, Cooper ME, Kahn SE, Marx N, et al. Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial. JAMA [Internet]. 2019 Jan 1 [cited 2021 Oct 27];321(1):69–79. Available from: https://jamanetwork.com/journals/jama/fullarticle/271464634. Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, et al. Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus. http://dx.doi.org/101056/NEJMoa1307684 [Internet]. 2013 Oct 2 [cited 2021 Oct 27];369(14):1317–26. Available from: https://www.nejm.org/doi/full/10.1056/nejmoa130768435. Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, et al. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. http://dx.doi.org/101056/NEJMoa1501352 [Internet]. 2015 Jul 15 [cited 2021 Oct 27];373(3):232–42. Available from: https://www.nejm.org/doi/full/10.1056/nejmoa150135236. Turner R. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). The Lancet [Internet]. 1998 Sep 12 [cited 2021 Oct 27];352(9131):854–65. Available from: http://www.thelancet.com/article/S0140673698070378/fulltext37. Lee K-T, Yeh Y-H, Chang S-H, See L-C, Lee C-H, Wu L-S, et al. Metformin is associated with fewer major adverse cardiac events among patients with a new diagnosis of type 2 diabetes mellitus: A propensity score-matched nationwide study. Medicine [Internet]. 2017 Jul 1 [cited 2021 Oct 27];96(28). Available from: /pmc/articles/PMC5515773/38. Asociación entre la edad del diagnóstico de diabetes tipo 2 y la gravedad del trastorno. Revista Panamericana de Salud Pública. 2003 Dec;14(6):434–5.39. Wilcox T, de Block C, Schwartzbard AZ, Newman JD. Diabetic Agents, From Metformin to SGLT2 Inhibitors and GLP1 Receptor Agonists: JACC Focus Seminar. Journal of the American College of Cardiology. 2020 Apr 28;75(16):1956–74.40. Palmer SC, Tendal B, Mustafa RA, Vandvik PO, Li S, Hao Q, et al. Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials. The BMJ [Internet]. 2021 Jan 13 [cited 2021 Oct 30];372. Available from: /pmc/articles/PMC7804890/41. Nunes JPL, Rodrigues JD, Mel o F. Acute myocardial infarction associated to DPP-4 inhibitors. Heart, Lung and Vessels [Internet]. 2014 [cited 2021 Oct 30];6(3):180. Available from: /pmc/articles/PMC4181279/42. Zheng SL, Roddick AJ, Aghar-Jaffar R, Shun-Shin MJ, Francis D, Oliver N, et al. Association Between Use of Sodium-Glucose Cotransporter 2 Inhibitors, Glucagon-like Peptide 1 93 Agonists, and Dipeptidyl Peptidase 4 Inhibitors With All-Cause Mortality in Patients With Type 2 Diabetes: A Systematic Review and Meta-analysis. JAMA [Internet]. 2018 Apr 17 [cited 2021 Oct 30];319(15):1580. Available from: /pmc/articles/PMC5933330/43. Scheen AJ. Cardiovascular Effects of New Oral Glucose-Lowering Agents: DPP-4 and SGLT-2 Inhibitors. Circulation Research [Internet]. 2018 May 1 [cited 2021 Oct 30];122(10):1439. Available from: /pmc/articles/PMC5959222/44. Galvus | European Medicines Agency [Internet]. [cited 2021 Dec 12]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/galvus45. Davies MJ, D’Alessio DA, Fradkin J, Kernan WN, Mathieu C, Mingrone G, et al. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2018 61:12 [Internet]. 2018 Oct 5 [cited 2022 Jan 28];61(12):2461–98. Available from: https://link.springer.com/article/10.1007/s00125-018-4729-546. Foretz M, Guigas B, Bertrand L, Pollak M, Viollet B. Metformin: From Mechanisms of Action to Therapies. Cell Metabolism [Internet]. 2014 Dec 2 [cited 2022 Jan 29];20(6):953–66. Available from: http://www.cell.com/article/S1550413114004410/fulltext47. Madiraju AK, Erion DM, Rahimi Y, Zhang XM, Braddock DT, Albright RA, et al. Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase. Nature [Internet]. 2014 [cited 2022 Jan 29];510(7506):542. Available from: /pmc/articles/PMC4074244/48. Foretz M, Guigas B, Viollet B. Understanding the glucoregulatory mechanisms of metformin in type 2 diabetes mellitus. Nature Reviews Endocrinology [Internet]. 2019 Aug 22 [cited 2022 Jan 29];15(10):569–89. Available from: https://www.hal.inserm.fr/inserm-0227718649. Bromage DI, Godec TR, Pujades-Rodriguez M, Gonzalez-Izquierdo A, Denaxas S, Hemingway H, et al. Metformin use and cardiovascular outcomes after acute myocardial infarction in patients with type 2 diabetes: a cohort study. Cardiovascular Diabetology [Internet]. 2019 Dec 9 [cited 2021 Oct 30];18(1). Available from: /pmc/articles/PMC6900858/50. Conceptos fundamentales de las revisiones sistemáticas/metaanálisis [Internet]. [cited 2021 Dec 12]. Available from: https://www.elsevier.es/es-revista-urologia-colombiana-398- pdf-S0120789X1500007651. Gamble J-M, Thomas JM, Twells LK, Midodzi WK, Majumdar SR. Comparative effectiveness of incretin-based therapies and the risk of death and cardiovascular events in 38,233 metformin monotherapy users. Medicine [Internet]. 2016 Jun 1 [cited 2021 Oct 30];95(26). Available from: /pmc/articles/PMC4937919/EstudiantesInvestigadoresORIGINAL53161452.2021.pdf53161452.2021.pdfTesis de Maestría en Ciencias - Farmacologíaapplication/pdf2344281https://repositorio.unal.edu.co/bitstream/unal/81150/5/53161452.2021.pdf14b9f26c2fa16be39eb724acc0d3ca7cMD55LICENSElicense.txtlicense.txttext/plain; charset=utf-84074https://repositorio.unal.edu.co/bitstream/unal/81150/6/license.txt8153f7789df02f0a4c9e079953658ab2MD56THUMBNAIL53161452.2021.pdf.jpg53161452.2021.pdf.jpgGenerated Thumbnailimage/jpeg5816https://repositorio.unal.edu.co/bitstream/unal/81150/7/53161452.2021.pdf.jpga1a93cb8acaa2710532fba776e2aefbfMD57unal/81150oai:repositorio.unal.edu.co:unal/811502023-08-02 23:03:51.561Repositorio Institucional Universidad Nacional de Colombiarepositorio_nal@unal.edu.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 |